TNGX Stock — Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (TNGX)

Updated October 16, 2026.

TNGX is a Stock. Total return is 115.4% over the past 6.1 years, 25.2 points behind SPY at 140.6%.

Tango Therapeutics is a precision oncology company focused on discovering and developing drugs for cancer patients with specific genetic profiles and unmet medical needs. The company's pipeline includes PRMT5 inhibitors in clinical trials for pancreatic, lung, and brain cancers, along with other targeted therapies designed to overcome tumor immune evasion. This is a clinical-stage biotech company with no established distribution history, making it oriented toward investors seeking exposure to early-stage drug development rather than current income.

TNGX performance versus SPY

Price and return data through 2026-10-16.

Total return is 115.4% over the past 6.1 years, 25.2 points behind SPY at 140.6%. Over the past year its total return — price change plus distributions reinvested — is 140.4%. Its deepest 1-year drawdown was 33.9%.

TNGX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/03/2020

Distribution frequency

None

Last close

$22.04 (as of 2026-10-16)

Market cap

$3,716,172,489

Average volume

3688261.0

Beta

1.17

Payout ratio

0.0%

EPS

$-0.85

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TNGX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 33.9%.

Who may consider TNGX — and who may not

It is a weaker fit for investors who need monthly cash flow (TNGX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TNGX

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions